Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...
Zacks Investment Research on MSN
Denali enters into a $275M funding deal with Royalty Pharma
Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
GlobalData on MSN
Denali makes $275m funding agreement with Royalty Pharma
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...
In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
Fintel reports that on December 5, 2025, Wedbush maintained coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform ...
Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.
Investing.com -- Denali Therapeutics Inc (NASDAQ:DNLI) stock rose 5.7% on Thursday after the company announced a $275 million synthetic royalty funding agreement with Royalty Pharma plc (NASDAQ:RPRX) ...
Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback